Egetis reports tiratricol lowers FT4 by 37% in retrospective RTH — beta study
Egetis Therapeutics announced publication of a retrospective study supporting tiratricol’s potential in resistance to thyroid hormone beta. The study included 28 patients, with median treatment lasting 50 months; results showed lower thyroid hormone levels and reduced heart rate. Findings support existing European trea